comparemela.com

Latest Breaking News On - Riccardo lencioni - Page 1 : comparemela.com

TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Italy
Riccardo-lencioni
Department-of-surgery
Cancers-symposium
Critical-area-pathology
Riccardo-lencioni
D
Chemoembolization-tace-
Urvalumab-imfinzi-
Nd-bevacizumab-avastin-
Hepatocellular-carcinoma
Hcc

Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC

vimarsana © 2020. All Rights Reserved.